Mobiquity Technologies Files SC 13D/A Amendment

TL;DR

Mobiquity Technologies filed a 13D/A amendment on Aug 6. Check ownership changes.

AI Summary

On August 6, 2024, Mobiquity Technologies, Inc. filed an amendment (Amendment #4) to its Schedule 13D. This filing relates to the common stock of the company. The filing was made by Gene Salkind, with Steven Morse, Esq. of Morse & Morse, PLLC acting as the authorized contact.

Why It Matters

This filing indicates a change in the beneficial ownership or reporting status of Mobiquity Technologies' stock, which could signal shifts in control or investment strategy.

Risk Assessment

Risk Level: medium — Schedule 13D filings often relate to significant changes in beneficial ownership, which can introduce volatility and uncertainty.

Key Numbers

• 0001683168-24-005964 — Accession Number (Unique identifier for the SEC filing)
• 20240822 — Filing Date (Date the filing was made with the SEC)

Key Players & Entities

• Mobiquity Technologies, Inc. (company) — Subject Company
• Gene Salkind (person) — Filing Person
• Steven Morse, Esq. (person) — Authorized Contact
• Morse & Morse, PLLC (company) — Legal Representative
• August 6, 2024 (date) — Date of Event

FAQ

Key Financial Figures

• $0.0001 — dule 13D relates are the common shares, $0.0001 par value per share (“Common Shar
• $2 — ng at a closing sale price in excess of $2 per share between July 24, 2024 and Aug

Filing Documents

• mobq_13da4.htm (SC 13D/A) — 37KB
• 0001683168-24-005964.txt ( ) — 39KB

(d) or 2(e)

ITEM 2(d) or 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States NUMBER OF 7 SOLE VOTING POWER 8,805,239 SHARES BENEFICIALLY 8 SHARED VOTING POWER 0 OWNED BY EACH 9 SOLE DISPOSITIVE POWER 8,805,239 REPORTING PERSON WITH 10 SHARED DISPOSITIVE POWER 0 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 8,805,239 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES /x/ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 53.1% (1) 14 TYPE OF REPORTING PERSON IN (1) Based upon approximately 16,006,000 common shares outstanding on August 8, 2024. CUSIP No. 60743F 607 SCHEDULE 13D Page 3 of 5 Pages

Security and Issuer

ITEM 1. Security and Issuer. The securities to which this Schedule 13D relates are the common shares, $0.0001 par value per share (“Common Shares”) of Mobiquity Technologies, Inc., a New York corporation (the “Issuer”). The address of the executive offices of the Issuer is 35 Torrington Lane, Shoreham, NY 11766.

Identity and Background

ITEM 2. Identity and Background. (a) – (c) This Statement is filed by Gene Salkind (on behalf of himself, his wife and a family trust), with an address c/o of 35 Torrington Lane, Shoreham, NY 11766. Dr. Salkind is a practicing neurosurgeon in Pennsylvania. (d) - (e) During the last five years, Dr. Salkind has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) nor has he been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding violations with respect to such laws. (f) Mr. Salkind is a United States citizen.

Source and Amount of Funds or Other Consideration

ITEM 3. Source and Amount of Funds or Other Consideration. Dr. Salkind, his wife, and a family trust used their personal funds to make investments in the Issuer over the last several years.

Purpose of Transaction

ITEM 4. Purpose of Transaction. Dr. Salkind is Chairman of the Board of the Issuer and a principal stockholder. Except as described above, Mr. Salkind presently has no plans or proposals which relate to or would result in any action enumerated in subparagraphs (a) through (j) of the instructions for Item 4 of Schedule 13D.

Interest in Securities of the Issuer

ITEM 5. Interest in Securities of the Issuer. (a), (b) Dr. Salkind, his wife, and a family trust beneficially own 8,805,239 common shares of the Issuer, including convertible notes, options and warrants to purchase an aggregate of 581,544 common shares. Such 8,805,239 common shares represent approximately 53.1% of the outstanding common shares of the Issuer. CUSIP No. 60743F 607 SCHEDULE 13D Page 4 of 5 Pages (c) During the last 60 days, all transactions between the reporting person and the Issuer are described in the Issuer’s Form 10-Q for the quarter ended June 30, 2024 which are incorporated by reference herein. In particular, the reporting person received 7,675,160 common shares upon the automatic conversion of 751,973 shares of Series H Preferred Stock based upon the Issuer’s common stock trading at a closing sale price in excess of $2 per share between July 24, 2024 and August 6, 2024. The 7,675,160 common shares received include 10 shares of common stock for every one share of Series H Preferred Stock which was canceled plus 155,430 common shares in accrued and unpaid dividends. (d) and (e) Not applicable.

Contracts, Arrangements, Understandings or

ITEM 6. Contracts, Arrangements, Understandings or Relationship with Respect to the Securities of the Issuer. No contracts, arrangements, understandings, or relationships (legal or otherwise) exist between Dr. Salkind and any person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.

Materials to be filed

ITEM 7. Materials to be filed as Exhibits . Not applicable. CUSIP No. 60743F 607 SCHEDULE 13D Page 5 of 5 Pages

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: August 21, 2024 By: /s/ Dr. Gene Salkind Dr. Gene Salkind

View Full Filing

View this SC 13D/A filing on SEC EDGAR